Besides, upregulation of FOXO1 could reduce the expression of IL-17A and IL-17RA in the liver immune microenvironment constructed by IRI and HCC recurrence, and inhibit the activation of the EMT program, cancer stemness and the formation of the pre-metastatic microenvironment at mRNA levels, thereby ameliorating the hepatic microenvironment (Fig. 7D–G). This evidence concerns the gene FOXO1 and cancer.